416 related articles for article (PubMed ID: 23818356)
1. Adjuvant chemotherapy after reduced craniospinal irradiation dose in children with average-risk medulloblastoma: a 5-year follow-up study.
Wahba HA; Abu-Hegazy M; Wasel Y; Ismail EI; Zidan AS
J BUON; 2013; 18(2):425-9. PubMed ID: 23818356
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
[TBL] [Abstract][Full Text] [Related]
3. Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study.
Friedrich C; von Bueren AO; von Hoff K; Kwiecien R; Pietsch T; Warmuth-Metz M; Hau P; Deinlein F; Kuehl J; Kortmann RD; Rutkowski S
Eur J Cancer; 2013 Mar; 49(4):893-903. PubMed ID: 23182688
[TBL] [Abstract][Full Text] [Related]
4. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study.
Packer RJ; Goldwein J; Nicholson HS; Vezina LG; Allen JC; Ris MD; Muraszko K; Rorke LB; Wara WM; Cohen BH; Boyett JM
J Clin Oncol; 1999 Jul; 17(7):2127-36. PubMed ID: 10561268
[TBL] [Abstract][Full Text] [Related]
5. Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol.
von Bueren AO; Friedrich C; von Hoff K; Kwiecien R; Müller K; Pietsch T; Warmuth-Metz M; Hau P; Benesch M; Kuehl J; Kortmann RD; Rutkowski S
Eur J Cancer; 2015 Nov; 51(16):2434-43. PubMed ID: 26254812
[TBL] [Abstract][Full Text] [Related]
6. Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy.
Sirachainan N; Nuchprayoon I; Thanarattanakorn P; Pakakasama S; Lusawat A; Visudibhan A; Dhanachai M; Larbcharoensub N; Amornfa J; Shotelersuk K; Katanyuwong K; Tangkaratt S; Hongeng S
J Clin Neurosci; 2011 Apr; 18(4):515-9. PubMed ID: 21310618
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
[TBL] [Abstract][Full Text] [Related]
8. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium.
Okada K; Soejima T; Sakamoto H; Hirato J; Hara J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28572. PubMed ID: 32710713
[TBL] [Abstract][Full Text] [Related]
10. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
11. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.
Packer RJ; Sutton LN; Elterman R; Lange B; Goldwein J; Nicholson HS; Mulne L; Boyett J; D'Angio G; Wechsler-Jentzsch K
J Neurosurg; 1994 Nov; 81(5):690-8. PubMed ID: 7931615
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
14. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
Packer RJ; Zhou T; Holmes E; Vezina G; Gajjar A
Neuro Oncol; 2013 Jan; 15(1):97-103. PubMed ID: 23099653
[TBL] [Abstract][Full Text] [Related]
15. Outcome and prognostic factors of radiation therapy for medulloblastoma.
Rieken S; Mohr A; Habermehl D; Welzel T; Lindel K; Witt O; Kulozik AE; Wick W; Debus J; Combs SE
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e7-e13. PubMed ID: 21345611
[TBL] [Abstract][Full Text] [Related]
16. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy.
Gupta T; Jalali R; Goswami S; Nair V; Moiyadi A; Epari S; Sarin R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1534-40. PubMed ID: 22342098
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Ridola V; Grill J; Doz F; Gentet JC; Frappaz D; Raquin MA; Habrand JL; Sainte-Rose C; Valteau-Couanet D; Kalifa C
Cancer; 2007 Jul; 110(1):156-63. PubMed ID: 17541945
[TBL] [Abstract][Full Text] [Related]
19. Adult medulloblastoma: multiagent chemotherapy.
Greenberg HS; Chamberlain MC; Glantz MJ; Wang S
Neuro Oncol; 2001 Jan; 3(1):29-34. PubMed ID: 11305414
[TBL] [Abstract][Full Text] [Related]
20. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
